By integrating the results of these 2 studies, the response rate of metastatic cSCC to cemiplimab was 46.7% (35/75 cases).[40] The clinical benefit of anti-PD-1 antibodies for rare malignant cutaneous epithelial tumors have also been reported by several case reports. The gene discussed is PDCD1; the disease is skin squamous cell carcinoma.